Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis

被引:15
作者
Azim, Hamdy A. [1 ,2 ]
Elghazawy, Hagar [2 ,3 ]
Ghazy, Ramy M. [4 ]
Abdelaziz, Ahmed H. [3 ]
Abdelsalam, Marwa [2 ]
Elzorkany, Amira [5 ]
Kassem, Loay [1 ,2 ]
机构
[1] Cairo Univ, Kasr Alainy Sch Med, Dept Clin Oncol, Giza, Egypt
[2] Cairo Oncol Ctr, Cairo, Egypt
[3] Ain Shams Univ, Dept Clin Oncol, Cairo, Egypt
[4] Alexandria Univ, High Inst Publ Hlth, Trop Hlth Dept, Alexandria, Egypt
[5] Training & Biostatist Adm, Minist Hlth & Populat, Alexandria, Egypt
关键词
WOMEN; STAGE; STATISTICS; CHINA; PROGNOSIS; CARCINOMA; SURVIVAL; AGE;
D O I
10.1200/GO.22.00387
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Breast cancer (BC) is the most common cancer among Egyptian females. No current national cancer database is available in Egypt to provide reliable data on the specific clinicopathologic features of BC in this population. Herein, we investigated the clinical profile of BC among Egyptian women. METHODS A systematic review of studies on BC published from inception until December 2021 was performed. We explored pooled estimated proportions of different stages of BC at presentation in Egypt and other clinicopathologic features including age, menopausal status, tumor (T) and lymph node (N) stages, and biological subtypes. Data analysis was performed using meta package (R). RESULTS Twenty-six studies were eligible for our systematic review and meta-analysis, including 31,172 BC cases. In 12 studies, including 15,067 patients with BC, the estimated mean age was 50.46 years (95% CI, 48.7 to 52.1; I-2, 99%), with a pooled proportion of premenopausal/perimenopausal women of 57% (95% CI, 50 to 63; I2, 98%). Among 9,738 patients with BC, pooled proportions of stage I, II, III, and IV were 6% (95% CI, 4 to 8; I-2, 90%), 37% (95% CI, 31 to 43; I-2, 93%), 45% (95% CI, 42 to 49; I-2, 78%), and 11% (95% CI, 9 to 15; I-2, 87%), respectively. The pooled proportions of patients with T3 and T4 tumors were 21% (95% CI, 14 to 31; I-2, 99%) and 8% (95% CI, 5 to 12; I-2, 96%), respectively, while those with positive lymph nodes were 70% (95% CI, 59 to 79; I-2, 99%). CONCLUSION Dominance of advanced stage and young age at diagnosis represented the two main features of BC among Egyptian women. Our data may serve to guide the policymakers in Egypt as well as other countries with lower resources to prioritize the diagnostic and therapeutic needs in this context.
引用
收藏
页数:11
相关论文
共 57 条
  • [1] Abbass H, 2011, Gastric & Breast Cancer, V10, P180
  • [2] Abd Aziz KK, 2015, Menoufia Med J, V28, P333
  • [3] Current treatment modalities of breast-cancer patients in Alexandria, Egypt
    Abdel-Fattah, M
    Lotfy, NS
    Bassili, A
    Anwar, M
    Mari, E
    Bedwani, R
    Tognoni, G
    [J]. BREAST, 2001, 10 (06) : 523 - 529
  • [4] Abdelaziz AH, 2018, ANN ONCOL, V29
  • [5] Abo-Touk NA, 2019, Forum Clin Oncol, V10, P26
  • [6] Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
    Allemani, Claudia
    Matsuda, Tomohiro
    Di Carlo, Veronica
    Harewood, Rhea
    Matz, Melissa
    Niksic, Maja
    Bonaventure, Audrey
    Valkov, Mikhail
    Johnson, Christopher J.
    Esteve, Jacques
    Ogunbiyi, Olufemi J.
    Azevedo e Silva, Gulnar
    Chen, Wan-Qing
    Eser, Sultan
    Engholm, Gerda
    Stiller, Charles A.
    Monnereau, Alain
    Woods, Ryan R.
    Visser, Otto
    Lim, Gek Hsiang
    Aitken, Joanne
    Weir, Hannah K.
    Coleman, Michel P.
    [J]. LANCET, 2018, 391 (10125) : 1023 - 1075
  • [7] [Anonymous], 2020, SEER Cancer Stat Facts: Female Breast Cancer
  • [8] [Anonymous], 2010, Chinese-German J Clin Oncol
  • [9] [Anonymous], 2011, Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training
  • [10] Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology
    Azim, Hamdy A.
    Abdel-Malek, Raafat
    Kassem, Loay
    [J]. CLINICAL BREAST CANCER, 2018, 18 (02) : E187 - E195